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complicated by recurrent bleediWe describe the first reported cases of phenytoin-related drug-induced 
hypersensitivity syndrome in unrelated Indigenous Australians with the same 
HLA-B*56:02 allele. These patients shared common clinical and pathological 
features, and all three were found to have the otherwise rare HLA-B allele, 
which might represent a novel genetic susceptibility factor for this syndrome.Clinical records
Patient 1
A 32-year-old Indigenous man from a remote Western
Australian community presented with a fever, diffuse
papular rash and oral ulceration, and a productive cough of
2 weeks’ duration. He was admitted to the intensive care
unit (ICU) for respiratory failure and hypotension. Pheny-
toin 300 mg daily had been prescribed 3 weeks earlier for
alcohol-associated seizures. He remained febrile with per-
sistent respiratory failure, and after 10 days he developed
profuse diarrhoea and transient hepatitis. Abdominal
imaging results were normal and screening tests for blood-
borne infections and autoimmune disease were negative.
Colonoscopy showed severely inflamed, oedematous
mucosa and confluent ulceration, with histological evi-
dence of widespread mucosal loss and granulation tissue
overlying inflamed superficial submucosa with prominent
cytomegalovirus (CMV) inclusions (Box 1 and Box 2).
It was discovered that he had attended a different
hospital 2 years earlier with a desquamating rash, oral
ulceration, peripheral eosinophilia, lymphadenopathy and
prolonged fever after starting phenytoin therapy. Delayed-
onset features had included diarrhoea (with colonic CMV
inclusions) and hepatitis. There was serological and
polymerase chain reaction (PCR) evidence of human
herpesvirus 6 (HHV-6) reactivation. A liver biopsy had
shown features of drug hypersensitivity. After withdrawal
of phenytoin treatment and starting treatment with pred-
nisolone and valganciclovir, he had been discharged 47
days after admission, and had been advised to avoid
phenytoin.
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henytoin treatment and
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blood transfusions. A further colonoscopy to investigate
the bleeding showed regenerative, hypervascular colonic
mucosa with reduced ulceration. After 11 weeks in the
intensive care unit, the patient deteriorated with refractory
hypotension and worsening respiratory failure, and died 2
days later.
Patient 2
A 33-year-old Indigenous man from Perth, Western Aus-
tralia, presented with a generalised desquamating rash
without mucosal involvement, and fever and abdominal
pain of 4 weeks’ duration, 3 months after commencing
phenytoin 300 mg daily for alcohol-related seizures. Inves-
tigations revealed hepatitis and eosinophilia, and gastros-
copy showed gastric ulceration with prominent CMV viral
inclusions. CMV and HHV-6 DNA were also detected in
whole blood. Phenytoin treatment was ceased and corti-
costeroid and ganciclovir treatment was started, followed
by oral valganciclovir until the CMV viraemia resolved. The
patient recovered fully.
Patient 3
A 43-year-old Indigenous woman from a remote Northern
Territory community presented with a cerebral abscess
requiring surgical drainage and intravenous phenytoin
prophylaxis 300 mg daily. She had an initially uneventful
recovery until 2 weeks postoperatively, when she became
progressively hypoxaemic, with bilateral pulmonary infil-
trates. She developed a desquamating rash, hepatitis,
eosinophilia and diarrhoea. Phenytoin treatment was
ceased and she was admitted to the ICU. She developed
progressive multiple organ failure and died 10 days later,
despite receiving maximal supportive therapy.
Discussion
For all three patients, human leukocyte antigen (HLA)
typing revealed HLA-B*56:02 as a common allele (includ-
ing one patient with an HLA-B*56:02-homozygous allele).
Although this allele is widely distributed globally, it is
generally rare.1 Among Indigenous Australians, localised
areas of high prevalence (more than 10%) have been found
in central Australia, although previous studies of Indige-
nous populations in WA, and in Arnhem Land in the411MJA 197 (7) · 1 October 2012
Clinical focusNorthern Territory, suggest a population prevalence of less
than 2%.1 Within the Australian Bone Marrow Donor
Registry (which has recently been enriched by involvement
of Indigenous Australian donors), HLA-B*56:02 is present
in 0.6% (173/29 067) of donors who have had DNA
sequencing performed at HLA-B.
The occurrence of this HLA-B allele in three unrelated
cases therefore appears exceptionally unlikely to have
occurred by chance alone, suggesting that it may be
appropriate to add it to an existing list of HLA-B alleles
marking genetic susceptibility to drug hypersensitivity
syndromes. This list includes HLA-B*57:01 (hypersensitiv-
ity to abacavir and flucloxacillin), B*58:01 (allopurinol),
B*15:02 (carbamazepine) and B*35:05 (nevirapine).2
These three cases are in keeping with diagnostic criteria
for drug-induced hypersensitivity syndrome (DIHS) (for-
merly known as drug reaction with eosinophilia and sys-
temic symptoms [DRESS] syndrome). Criteria include:
• delayed-onset rash 2–6 weeks after initial drug exposure
• haematological abnormalities (eosinophilia and/or
atypical lymphocytosis)
• systemic features with prolonged fever and/or lymph-
adenopathy as well as organ involvement (most frequently
hepatitis, but also gastrointestinal, lung and kidney
involvement).
Expanded diagnostic criteria acknowledge the diag-
nostic value of prolonged clinical symptoms 2 weeks after
drug discontinuation. The prolonged clinical symptoms
may reflect the role of herpesvirus reactivation in the
perpetuation of hypersensitivity responses.3 Anticonvul-
sants are frequently implicated in DIHS, and in the case
of carbamazepine-associated DIHS, there is evidence of
HLA-associated susceptibility (in this case, with HLA-
A*31:01).4
Patients may develop two or three features of the syn-
drome at one time, with symptom resolution in one organ
often followed by development of symptoms in another
organ system.5 DIHS and Stevens–Johnson syndrome
share some features, including their delayed onset and
prolonged course.6 However, mucocutaneous signs are
more common in Stevens–Johnson syndrome, especially
in the mouth and eyes, but facial oedema and small
pustules are more typical of DIHS.7 In contrast, herpes-
virus reactivation, hepatitis and other visceral involvement
are more strongly associated with DIHS.
One unusual aspect of DIHS is the relationship
between immune-mediated drug reactions and the reacti-
vation of herpesviruses infection. This is particularly so for
HHV-6 as well as CMV and Epstein–Barr virus (EBV),
which may explain why organ involvement and systemic
inflammation may be delayed in onset and prolonged
after discontinuation of the offending drug. Real-time
PCR analyses of subjects with DIHS have shown that
various herpesviruses can sequentially reactivate during
the syndrome, often initially HHV-6 or EBV, then HHV-7
and later CMV.8 Such a cascade of sequential reactivation
is also seen in graft-versus-host disease.9 It seems likely in
these cases that HLA-B*56:02 is involved in binding and
presenting phenytoin (or a metabolite of phenytoin) to T-
cells, although there are several possible mechanisms for
HLA-restricted immune responses to drugs.10 In the con-
text of DIHS, there is additional evidence that antiviral T-
cells may also be affected by this process, so that delayed
tissue injury may be mediated by pro-inflammatory anti-
viral immune responses rather than by the viruses them-
selves.5 The immunological basis for these reactions —
and the temporal relationships between virus-specific
and drug-specific immune responses — have not been
completely elucidated. However, it is notable that B-cell
depletion and hypogammaglobulinaemia are also found
early in the clinical course of DIHS. One possible explana-
tion for these B-cell abnormalities, in a syndrome that is
otherwise thought to involve drug-specific T-cell
responses, is that regulatory T-cell populations are prefer-
entially involved in the early immune response.11
Mortality associated with DIHS is 10%–20%. Diagnostic
awareness is therefore critical — including awareness of
the potential for both delayed-onset and prolonged mani-
festations that may otherwise be viewed as atypical for a
drug hypersensitivity syndrome. Previous experience with
HLA-associated drug hypersensitivity reactions has dem-
onstrated the contribution of genetic testing strategies
towards improved vigilance and diagnostic accuracy. We
believe that the novel finding of three patients with the
same HLA-B*56:02 allele warrants further investigation in
an expanded case series.
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2 Colonic biopsy sample from Patient 1, showing a positive 
immunohistochemical test for cytomegalovirus (CMV) 
(dark brown spots are areas of CMV), in association with 
severe colonic inflammation
1 Colonic biopsy sample from Patient 1, showing complete 
loss of mucosa, leaving inflamed granulation tissue over 
intact muscularis mucosa (haematoxylin and eosin stain)MJA 197 (7) · 1 October 2012412
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